• LAST PRICE
    17.0000
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    ---/ ---
  • Ask / Lots
    ---/ ---
  • Open / Previous Close
    0.0000 / 17.0000
  • Day Range
    ---
  • 52 Week Range
    Low 16.5500
    High 25.9500
  • Volume
    ---
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Friday's close: 16.89
TimeVolumeAVBP
09:32 ET31316.88
09:36 ET70016.975
09:38 ET50016.975
09:39 ET200016.925
09:41 ET790016.935
09:45 ET30016.945
09:48 ET3730516.88
09:50 ET125316.59
09:54 ET40016.69
09:56 ET228617
09:57 ET10017.21
09:59 ET3813816.86
10:06 ET10017
10:10 ET200017
10:19 ET50017.0448
10:21 ET60017.27
10:24 ET10017.175
10:28 ET110017.175
10:30 ET50017.175
10:32 ET1027417
10:37 ET10016.9
10:44 ET20017.05
10:46 ET30017.04
10:48 ET60017.05
10:50 ET130017.12
10:51 ET775317
10:55 ET10017.05
11:00 ET360617
11:02 ET20017.09
11:04 ET1140017.05
11:09 ET10017.095
11:11 ET90017.06
11:13 ET70017.09
11:18 ET310017.15
11:20 ET147817.15
11:22 ET270017.2
11:26 ET70017.25
11:27 ET60017.25
11:29 ET10017.31
11:31 ET20817.35
11:33 ET603417.04
11:42 ET20017.09
11:45 ET297116.92
11:56 ET190016.98
11:58 ET387317
12:02 ET40017.045
12:03 ET90017
12:05 ET630017.04
12:09 ET169617.04
12:16 ET108317.1
12:18 ET10017.095
12:21 ET20017.13
12:23 ET10017.14
12:25 ET230017.1548
12:30 ET50017.16
12:32 ET385617.13
12:38 ET10017.1
12:39 ET10017.18
12:45 ET10017.02
12:50 ET20017.125
12:52 ET150017.21
12:57 ET10017.16
01:03 ET131517.2
01:06 ET67617.2
01:08 ET126717.225
01:10 ET34217.2
01:14 ET290017.135
01:15 ET30017.09
01:19 ET10017
01:24 ET10017.02
01:28 ET30017.05
01:35 ET60017.04
01:37 ET30017.055
01:39 ET242817.15
01:44 ET114217.21
01:55 ET30017.15
01:57 ET80017.19
02:02 ET100017.15
02:08 ET20017.2
02:09 ET769216.9
02:20 ET30017
02:24 ET10017
02:26 ET40817.02
02:27 ET190017.14
02:33 ET10017.15
02:36 ET10017.12
02:38 ET50017.2
02:40 ET100017.22
02:42 ET10017.205
02:47 ET70017.25
02:49 ET1053217
02:51 ET10017
02:54 ET10016.98
02:56 ET540016.96
02:58 ET30016.82
03:02 ET20016.905
03:03 ET787016.765
03:05 ET30016.73
03:16 ET20016.77
03:18 ET40016.83
03:20 ET20016.875
03:21 ET10016.885
03:23 ET20016.89
03:25 ET220017
03:32 ET160016.92
03:34 ET170017.025
03:36 ET130017.12
03:38 ET10017.05
03:39 ET130017.23
03:41 ET110017.04
03:43 ET30017.04
03:45 ET28817.11
03:48 ET50017.11
03:50 ET70017.085
03:52 ET359216.865
03:54 ET90017
03:56 ET276616.97
03:57 ET110016.92
03:59 ET2201217
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesAVBP
Arrivent Biopharma Inc
569.4M
-7.8x
---
United StatesCMPS
Compass Pathways PLC
568.6M
-3.5x
---
United StatesCELC
Celcuity Inc
550.9M
-6.7x
---
United StatesPHAT
Phathom Pharmaceuticals Inc
586.4M
-2.6x
---
United StatesOCS
Oculis Holding AG
501.0M
0.0x
---
United StatesSLRN
ACELYRIN Inc
543.0M
-0.5x
---
As of 2024-04-16

Company Information

ArriVent Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. Its lead development candidate, Furmonertinib, and advance a pipeline of novel therapeutics, such as antibody drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors. Furmonertinib is an oral, highly brain-penetrant, active mutation-selective EGFR inhibitor that targets both classical (exon 19 deletion and L858R) and uncommon EGFR mutations, including exon 20 insertion mutations, as well as HER2 exon 20 insertion mutations. Furmonertinib is an investigational, novel, EGFR mutant-selective tyrosine kinase inhibitor that is developing for the treatment of NSCLC patients across a set of EGFR mutations. It is also focused on development and commercialization of the ARR-002 program.

Contact Information

Headquarters
18 Campus Blvd., Suite 100NEWTOWN SQUARE, PA, United States 19073-3269
Phone
240-780-6356
Fax
302-636-5454

Executives

Chairman of the Board, President, Chief Executive Officer
Zhengbin Yao
Chief Financial Officer, Treasurer
Winston Kung
Chief Operating Officer
Robin Lachapelle
Chief Technology Officer
Yang Wang
General Counsel, Secretary
James Kastenmayer

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$569.4M
Revenue (TTM)
$0.00
Shares Outstanding
33.5M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-2.17
Book Value
$4.73
P/E Ratio
-7.8x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.